Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Casi Pharmaceuticals, Inc.

Clinical trials sponsored by Casi Pharmaceuticals, Inc., explained in plain language.

CASI Pharmaceuticals, Inc. CASIF OTC

Biopharmaceutical company focused on developing and commercializing therapies for cancer and other diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1

New drug aims to stop kidney transplant rejection

Disease control Recruiting now

This study tests a new medicine called CID-103 in adults whose kidney transplants are being rejected by their immune system (antibody-mediated rejection). The trial has two parts: first, to find a safe dose, and second, to see if the drug can stop the rejection. About 58 people w…

Phase: PHASE1, PHASE2 • Sponsor: CASI pharmaceuticals, Inc. • Aim: Disease control

Last updated Jul 24, 2026 00:00 UTC